Emergent BioSolutions (EBS) Cash from Investing Activities Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 8.16% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 26.15% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 51.85% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 75.05% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 33.33% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -129.09% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -2.94% |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn | 45.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.83% |
| Dec 31, 2025 | 55.88% |
| Sep 30, 2025 | 76.78% |
| Jun 30, 2025 | 36.37% |
| Mar 31, 2025 | 56.70% |
| Dec 31, 2024 | 37.94% |
| Sep 30, 2024 | 59.12% |
| Jun 30, 2024 | 59.05% |
| Mar 31, 2024 | 42.26% |
| Dec 31, 2023 | 32.40% |
| Sep 30, 2023 | 25.50% |
| Jun 30, 2023 | 97.59% |
| Mar 31, 2023 | 14.55% |
| Dec 31, 2022 | -7.94% |
| Sep 30, 2022 | -160.86% |
| Jun 30, 2022 | -10.03% |
| Mar 31, 2022 | -14.59% |
| Dec 31, 2021 | 62.21% |
| Sep 30, 2021 | -28.36% |
| Jun 30, 2021 | -82.63% |